News & Events
-
July 16, 2017
The Coalition Against Major Diseases: Towards U.S. FDA qualification of hippocampal volume as a biomarker for enrichment in clinical trials for pre-dementia stages of Alzheimer’s disease
Conrado, D.J., et al.; “The Coalition Against Major Diseases: Towards U.S. FDA qualification of hippocampal volume as a biomarker for enrichment in clinical trials for pre-dementia stages of Alzheimer’s disease.” Alzheimer’s Association International Conference, London, UK, July 16-20, 2017, Alzheimer’s & Dementia 12(7): Suppl., 1259.... -
May 18, 2017
Enabling Integration of Alzheimer Disease (AD) Prevention Study Data by Application of CDISC Standards: Extension to Biometric Monitoring Device (BMD) Assessments
Arnerić, S.P., et al.; “Enabling Integration of Alzheimer Disease (AD) Prevention Study Data by Application of CDISC Standards: Extension to Biometric Monitoring Device (BMD) Assessments”. Arizona Alzheimer’s Consortium Annual Meeting, Phoenix, AZ, May 18, 2017.... -
March 29, 2017
The Coalition Against Major Diseases: Expanding its clinical trial database to support a disease progression model for pre-dementia
Romero, K., et al.; “The Coalition Against Major Diseases: Expanding its clinical trial database to support a disease progression model for pre-dementia”. The 13th International Conference on Alzheimer’s & Parkinson’s Diseases, Vienna, Austria, March 29 to April 2, 2017.... - August 21, 2015
-
February 5, 2015
The Choice of Outcome Parameters and Need for Distinct Assessment Tools with Regard to the Different Disease Stages in Alzheimer’s Disease (Video)
Presenter – Martha Brumfield, PhD, President and CEO, Critical Path Institute Conference – European Medicines Agency workshop on the clinical investigation of medicines for the treatment of Alzheimer’s disease; November 24-25, 2014; London, UK Video courtesy of the European Medicines Agency. ...